Moderna

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2010-01-01

Employees: 5.6K

Market Cap: $30.3B

Website: http://www.modernatx.com

Introduction: Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company...

Clinical Trials

Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT and SPIKEVAX X Injection.

Recruiting

Conditions: SARS-CoV-2

Interventions: Biological: SPIKEVAX Bivalent
Biological: SPIKEVAX X

First Posted Date: 2024-03-27

Last Posted Date: 2024-03-27

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 3300

Registration Number: NCT06333704

Locations: 🇰🇷
Sinsegie ENT Clinic, Busan, Korea, Republic of
🇰🇷
Kium Children Hospital, Gunsan, Jeollabuk-do, Korea, Republic of
🇰🇷
Jeil Family Medicine Clinic, Gwangju, Korea, Republic of

and more 21 locations

Study to Investigate Safety and Tolerability of mRNA-0184 Administered at 2 Different Infusion Durations in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: mRNA-0184

First Posted Date: 2024-02-06

Last Posted Date: 2024-08-26

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 40

Registration Number: NCT06243770

Locations: 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia

A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)

Active, not recruiting

Conditions: Myocarditis

First Posted Date: 2024-01-03

Last Posted Date: 2024-01-03

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 1500

Registration Number: NCT06189053

Locations: 🇺🇸
Veradigm, Chicago, Illinois, United States

A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria

Phase 1

Withdrawn

Conditions: Phenylketonuria

Interventions: Drug: mRNA-3210

First Posted Date: 2023-11-28

Last Posted Date: 2024-10-22

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 54

Registration Number: NCT06147856

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

Phase 2

Recruiting

Conditions: Respiratory Syncytial Virus

Interventions: Biological: mRNA-1345
Biological: Placebo

First Posted Date: 2023-11-22

Last Posted Date: 2024-05-22

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 360

Registration Number: NCT06143046

Locations: 🇺🇸
SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS, Dothan, Alabama, United States
🇺🇸
Abby's Research Institute, Phoenix, Arizona, United States
🇺🇸
Applied Research Center of Arkansas - ClinEdge - PPDS, Little Rock, Arkansas, United States

and more 50 locations

A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients

Phase 2

Withdrawn

Conditions: Cytomegalovirus Infection

Interventions: Biological: mRNA-1647
Biological: Placebo

First Posted Date: 2023-11-15

Last Posted Date: 2024-03-15

Lead Sponsor: ModernaTX, Inc.

Registration Number: NCT06133010

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

Completed

Conditions: SARS-CoV-2

Interventions: Biological: SPIKEVAX

First Posted Date: 2023-11-14

Last Posted Date: 2024-12-19

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 15196685

Registration Number: NCT06130345

Locations: 🇺🇸
Aetion, Inc, New York, New York, United States

A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine

Active, not recruiting

Conditions: Myocarditis, Pericarditis

Interventions: Biological: mRNA-1273

First Posted Date: 2023-11-02

Last Posted Date: 2024-11-05

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 1500

Registration Number: NCT06113692

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇪🇸
FISABIO, Valencia, Spain
🇳🇴
University of Oslo, Oslo, Norway

and more 2 locations

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Phase 2

Active, not recruiting

Conditions: Respiratory Syncytial Virus

Interventions: Biological: mRNA-1345
Biological: Placebo

First Posted Date: 2023-10-24

Last Posted Date: 2024-11-27

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 340

Registration Number: NCT06097299

Locations: 🇺🇸
Javara, Inc., Fayetteville, Georgia, United States
🇺🇸
ASCADA Research, LLC - Family Medicine, Fullerton, California, United States
🇺🇸
Velocity Clinical Research Metairie, Metairie, Louisiana, United States

and more 47 locations

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

Phase 3

Completed

Conditions: SARS-CoV-2
Influenza

Interventions: Biological: Influenza Vaccine
Biological: mRNA-1083
Biological: Placebo
Biological: COVID-19 Vaccine

First Posted Date: 2023-10-24

Last Posted Date: 2024-06-24

Lead Sponsor: ModernaTX, Inc.

Target Recruit Count: 8075

Registration Number: NCT06097273

Locations: 🇺🇸
Artemis Institute For Clinical Research LLC - Riverside - Headlands - PPDS, Riverside, California, United States
🇺🇸
Great Lakes Research Institute, Southfield, Michigan, United States
🇺🇸
DM Clinical Research - Southfield - ERN - PPDS, Southfield, Michigan, United States

and more 142 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy